Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 299

Results For "IP"

11081 News Found

Biocon Pharma gets FDA nod for arthritis drug Tofacitinib ER
Drug Approval | November 23, 2025

Biocon Pharma gets FDA nod for arthritis drug Tofacitinib ER

Tofacitinib extended-release tablets are a Janus kinase inhibitor indicated for Rheumatoid Arthritis


ACG unveils patent-clean laminate ‘DryPod’ to shake up moisture-protection market
R&D | November 23, 2025

ACG unveils patent-clean laminate ‘DryPod’ to shake up moisture-protection market

The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules


Rafa Laboratories lands $186 million BARDA contract to develop life-saving trauma drug
R&D | November 23, 2025

Rafa Laboratories lands $186 million BARDA contract to develop life-saving trauma drug

Landmark studies have shown that rapid TXA administration can significantly reduce mortality


FDA approves combo therapy for Cisplatin-ineligible muscle-invasive bladder cancer patients
Drug Approval | November 23, 2025

FDA approves combo therapy for Cisplatin-ineligible muscle-invasive bladder cancer patients

The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy


AstraZeneca to invest $2 billion in Maryland manufacturing expansion
News | November 22, 2025

AstraZeneca to invest $2 billion in Maryland manufacturing expansion

The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan


Lilly expands biotech footprint with new Gateway Labs in Philadelphia
R&D | November 21, 2025

Lilly expands biotech footprint with new Gateway Labs in Philadelphia

The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies


FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer
Drug Approval | November 21, 2025

FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer

HER2-mutant NSCLC typically has a poor prognosis and limited treatment options